Obstetrics & Gynaecology Search
Obstetrics & Gynaecology Obstetrics & Gynaecology
breast%20cancer
BREAST CANCER
Treatment Guideline Chart
Breast cancer is the presence of a malignant breast nodule, mass or abscess.
Most common symptom of breast cancer is a new lump or mass in the breast. The lump or mass is usually painless, hard and irregular but it can also be tender, soft, rounded or painful.
Other signs and symptoms include breast pain or nipple pain, nipple discharge, nipple retraction and presence of breast skin changes (eg peau d' orange, nipple excoriation, scaling, inflammation, skin tethering, ulceration, abscess).

Breast Cancer References

  1. Association of Breast Surgery @ BASO, Royal College of Surgeons of England. Guidelines for the management of symptomatic breast disease. Eur J Surg Oncol. 2005 May;31(Supp 1):1-21
  2. Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007 Jul;18(7):1133-1144. PMID: 17675394
  3. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006 Dec;355(26):2733-2743. PMID: 17192538
  4. Kataja V, Castiglione M; ESMO Guidelines Working Group. Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009 May;20(Suppl 4):10-14. doi: 10.1093/annonc/mdp114. PMID: 19454421
  5. AJCC cancer staging manual. In: Edge SB, Byrd DR, Compton CC, et al. 7th. http://www.springer.com/medicine/surgery/cancer+staging?SGWID=0-40654-0-0-0
  6. MedWormhttp://www.medworm.com/rss/index.php/OBGYN/29/http://www.medworm.com/rss/medicalfeeds/specialities/OBGYN.xml
  7. MedWormhttp://www.medworm.com/rss/index.php/Cancer-%26-Oncology/6/http://www.medworm.com/rss/medicalfeeds/specialities/Cancer-Oncology.xml
  8. American Cancer Society (ACS). Breast cancer: early detection. ACS. http://www.cancer.org. Aug 2012.
  9. Ministry of Health Malaysia, Academy of Medicine Malaysia. Clinical practice guidelines. Management of breast cancer, 2nd edition. http://www.acadmed.org.my. Nov 2010. Accessed 12 Sep 2012.
  10. National Collaborating Centre for Primary Care. Familial breast cancer. The classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care. NICE. http://www.nice.org.uk. Jul 2006. Accessed 11 Mar 2010.
  11. National Institute for Health and Care Excellence. Guidance on cancer services: improving outcomes in breast cancer manual update. NICE. http://www.nice.org.uk. Aug 2002. Accessed 11 Mar 2010.
  12. National Institute for Health and Care Excellence. NICE technology appraisal guidance 112. Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer. NICE. http://guidance.nice.org.uk. Nov 2006.
  13. National Collaborating Centre for Cancer. Advanced breast cancer: diagnosis and treatment. NICE. http://www.nice.org.uk. Feb 2009. Accessed 11 Mar 2010.
  14. National Collaborating Centre for Cancer. Early and locally advanced breast cancer: diagnosis and treatment. NICE. http://www.nice.org.uk. Feb 2009. Accessed 11 Mar 2010.
  15. Cardoso F, Harbeck N, Fallowfield L, et al; ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012 Oct;23(Suppl Suppl 7):vii11-9. doi: 10.1093/annonc/mds232. Accessed 26 Feb 2014. PMID: 22997442
  16. Goldhirsch A, Winer EP, Coates AS, et al; Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2013. Ann Oncol. 2013 Sep;24(9):2206-2223. doi: 10.1093/annonc/mdt303. Accessed 26 Feb 2014. PMID: 23917950
  17. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer. Version 3.2014 . NCCN. http://www.nccn.org.
  18. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer risk reduction. Version 1.2014. NCCN. http://www.nccn.org. Accessed 18 Sep 2014.
  19. Senkus E, Kyriakides S, Penault-Llorca F, et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24(Suppl 6):vi7-vi23. doi: 10.1093/annonc/mdt284. PMID: 23970019
  20. Wolff AC, Hammond MEH, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013 Nov;31(31):3997-4013. doi: 10.1200/JCO.2013.50.9984. Accessed 24 Oct 2013. PMID: 24101045
  21. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Breast cancer screening and diagnosis guidelines. Version 1.2012. NCCN. 2012.
  22. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Breast cancer version 3.2015. NCCN. http://www.nccn.org. 16 Jul 2015. Accessed 11 Aug 2015.
  23. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Breast cancer risk reduction. Version 2.2015. NCCN. http://www.nccn.org. 30 Jun 2015. Accessed 12 Aug 2015.
  24. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer version 2.2016. NCCN. https://www.nccn.org. 06 May 2016. Accessed 28 Jul 2016.
  25. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer risk reduction version 1.2016. NCCN. https://www.nccn.org. 23 Feb 2016. Accessed 28 Jul 2016.
  26. Pritchard KI. Adjuvant endocrine therapy for non-metastatic, hormone receptor-positive breast cancer. UpToDate. https://www.uptodate.com. 19 Jul 2016. Accessed 04 Aug 2016.
  27. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis version 1.2016 - July 27, 2016. NCCN. https://www.nccn.org. 27 Jul 2016.
  28. Cardoso F, Costa A, Senkus E, et al. 3rd ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 3). Ann Oncol. 2017 Jan 1;28(1):16-33. doi: 10.1093/annonc/mdw544. Accessed 10 Mar 2017. PMID: 28177437
  29. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer risk reduction version 2.2018. NCCN. https://www.nccn.org/. 23 Apr 2018. Accessed 09 Jul 2018.
  30. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer version 1.2018. NCCN. https://www.nccn.org/. 20 May 2018. Accessed 09 Jul 2018.
  31. Smith BD, Bellon JR, Blitzblau R, et al. Radiation therapy for the whole breast: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. ASTRO. https://www.astro.org/. 2018. Accessed 09 Jul 2018.
  32. Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019 Jun. doi: 10.1093/annonc/mdz173. Accessed 06 Nov 2019. PMID: 31161190
  33. Cardoso F, Senkus E, Costa A, et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann Oncol. 2018 Aug;29(8):1634-1657. doi: 10.1093/annonc/mdy192. Accessed 06 Nov 2019. PMID: 30032243
  34. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Genetic/familial high-risk assessment: Breast and ovarian. Version 3.2019. NCCN. https://www.nccn.org/. Jan 2019. Accessed 06 Nov 2019.
  35. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Breast cancer. Version 3.2019. NCCN. https://www.nccn.org/. Sep 2019.
  36. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Breast cancer risk reduction. Version 1.2019. NCCN. https://www.nccn.org/. Dec 2018.
  37. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Breast cancer screening and diagnosis. Version 1.2019. NCCN. https://www.nccn.org/. May 2019. Accessed 06 Nov 2019.
  38. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Breast cancer. Version 4.2020. NCCN. https://www.nccn.org/. May 2020.
  39. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Breast cancer. Version 3.2020. NCCN. https://www.nccn.org/. Mar 2020.
  40. Ministry of Health Malaysia, Academy of Medicine Malaysia. Clinical practice guidelines. Management of breast cancer. Third edition. Academy of Medicine Malaysia. http://www.acadmed.org.my/. 2019.
  41. Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020 Dec;31(12):1623-1649. doi: 10.1016/j.annonc.2020.09.010. PMID: 32979513
  42. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Breast cancer. Version 1.2021. NCCN. https://www.nccn.org/. Jan 2021. Accessed 26 Feb 2021.
  43. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Breast cancer risk reduction. Version 1.2020. NCCN. https://www.nccn.org/. May 2020.
  44. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Breast cancer screening and diagnosis. Version 1.2020. NCCN. https://www.nccn.org/. Sep 2020.
  45. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Genetic/familial high-risk assessment: Breast, ovarian, and pancreatic. Version 2.2021. NCCN. https://www.nccn.org/. Nov 2020.
  46. Park YH, Senkus-Konefka E, Im SA, et al. Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. Ann Oncol. 2020 Apr;31(4):451-469. doi: 10.1016/j.annonc.2020.01.008. Accessed 26 Feb 2021. PMID: 32081575
  47. Canadian Cancer Society. Risk of recurrence after surgery and additional treatments. Canadian Cancer Society. https://www.cancer.ca. 2021.
  48. Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant chemotherapy, endocrine therapy and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol. 2021 Jan;39(13):1485-1505. doi: 10.1200/jco.20.03399. PMID: 33507815
  49. Mannell A. An overview of risk factors for recurrent breast cancer. S Afr J Surg. 2017 Mar;55(1):29-34. PMID: 28876555
  50. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Breast cancer. Version 5.2021. NCCN. https://www.nccn.org/. 28 Jun 2021.
  51. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Breast cancer risk reduction. Version 1.2021. NCCN. https://www.nccn.org/. 24 Mar 2021.
  52. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Breast cancer screening and diagnosis. Version 1.2021. NCCN. https://www.nccn.org/. 06 May 2021.
  53. Rossi PG, Lebeau A, Canelo-Aybar C, et al. Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative. Br J Cancer. 2021 Apr;124(9):1503-1512. doi: 10.1038/s41416-020-01247-z. PMID: 33597715
  54. Sabel MS, Hirsch A, Bellon JR. Clinical manifestations and evaluation of locoregional recurrences of breast cancer. UpToDate. https://www.uptodate.com. 03 Feb 2021.
  55. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines): Breast cancer. Version 8.2021. NCCN. https://www.nccn.org/. 13 Sep 2021. Accessed 18 Oct 2021.
  56. Gennari A, André F, Barrios CH, et al; ESMO Guidelines Committee. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021 Dec;32(12):1475-1495. doi: 10.1016/j.annonc.2021.09.019. Accessed 11 Apr 2022. PMID: 34678411
  57. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Breast cancer. Version 2.2022. NCCN. https://www.nccn.org/. Dec 2021. Accessed 11 Apr 2022.
  58. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Breast cancer. Version 3.2022. NCCN. https://www.nccn.org/. May 2022. Accessed 26 May 2022.
  59. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Breast cancer risk reduction. Version 1.2022. NCCN. https://www.nccn.org/. Jan 2022. Accessed 26 May 2022.
  60. Eisen A, Somerfield MR, Accordino MK, et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: ASCO-OH (CCO) guideline update. J Clin Oncol. 2022 Mar;40(7):787-800. doi: 10.1200/JCO.21.02647. PMID: 35041467
  61. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): Breast cancer. Version 4.2022. NCCN. https://www.nccn.org/. Jun 2022.
  62. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): Breast cancer risk reduction. Version 1.2023. NCCN. https://www.nccn.org/. Oct 2022.
  63. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): Genetic/familial high-risk assessment: Breast, ovarian, and pancreatic. Version 1.2023. NCCN. https://www.nccn.org/. Sep 2022.
  64. Periodic Health Examination Task Force 2021. Philippine guidelines on periodic health examination: screening for neoplastic diseases. Department of Health Philippines. https://doh.gov.ph. 2021.
  65. Burstein HJ, DeMichele A, Somerfield MR, et al. Testing for ESR1 mutations to guide therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 2023 Jun;41(18):3423-3425. doi: 10.1200/JCO.23.00638. PMID: 37196213
  66. Department of Health (DOH) Philippines. Breast cancer national clinical practice guidelines. DOH Philippines. https://doh.gov.ph. 2022. Accessed 29 May 2023.
  67. Giordano SH, Franzoi MAB, Temin S, et al. Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update. J Clin Oncol. 2022 Aug;40(23):2612-2635. doi: 10.1200/JCO.22.00519. PMID: 35640077
  68. Moy B, Rumble RB, Carey LA; Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer Expert Panel. Chemotherapy and targeted therapy for endocrine-pretreated or hormone receptor-negative metastatic breast cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 2023 Feb;41(6):1318-1320. doi: 10.1200/JCO.22.02807. PMID: 36626701
  69. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology (NCCN guidelines): breast cancer. Version 4.2023. NCCN. https://www.nccn.org/. 23 Mar 2023.
Editor's Recommendations
Special Reports
MORE Special Reports arrow
Related Disease News
MORE Disease News arrow